SIS
LOGC

Sound Income Strategies’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Sound Income Strategies’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-658
Closed -$5K – 1069
2020
Q4 		$5K Hold
658
– – ﹤0.01% 599
2020
Q3 		$6K Buy
+658
New +$4.99K ﹤0.01% 528

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Sound Income Strategies's LOGC Position: Q1 2021 in Review

Sound Income Strategies sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2021, closing a stake of 658 shares — an estimated $5K sold.

Sound Income Strategies first reported a position in LOGC in Q3 2020 and held it in 2 quarters. The position peaked at $6K in Q3 2020. 61 funds tracked by Wall St. Rank hold LOGC as of Q1 2021.

  • Sound Income Strategies reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Sound Income Strategies sold 658 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $5K.
  • Sound Income Strategies first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Sound Income Strategies's LogicBio Therapeutics, Inc. Common Stock position peaked at $6K in Q3 2020.
  • 61 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Sound Income Strategies's 13F filing for Q1 2021, filed 14 Apr 2021.